{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:57:48Z","timestamp":1794887868725,"version":"4.9.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Metab"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Preclinical studies have shown that asparagine deprivation enhances T cell antitumour responses. Here we apply compassionate use of\n                    <jats:sc>l<\/jats:sc>\n                    -asparaginase, usually employed to treat blood malignancies, on patients with recurrent metastatic nasopharyngeal carcinoma. The use of\n                    <jats:sc>l<\/jats:sc>\n                    -asparaginase notably enhances immune-checkpoint blockade therapy in patients by strengthening CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell fitness. Our study shows that this combination is a promising avenue for clinical application and provides further mechanistic insight into how asparagine restriction rewires T cell metabolism.\n                  <\/jats:p>","DOI":"10.1038\/s42255-025-01245-6","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T05:03:59Z","timestamp":1741151039000},"page":"918-927","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Asparagine deprivation enhances T cell antitumour response in patients via ROS-mediated metabolic and signal adaptations"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3478-5777","authenticated-orcid":false,"given":"Hsuan-Chia","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Ying","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Lung","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0575-914X","authenticated-orcid":false,"given":"Tzong-Shyuan","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2006-133X","authenticated-orcid":false,"given":"Mei-Ling","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ming","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2536-6370","authenticated-orcid":false,"given":"Hsiang-Yu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Ju","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Jin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu-Han","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ching","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8803-4435","authenticated-orcid":false,"given":"Yu-Wen","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand Chin-Ming","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Rui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3078-3774","authenticated-orcid":false,"given":"Ping-Chih","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6826-9717","authenticated-orcid":false,"given":"Huang-Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"1245_CR1","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.semcancer.2022.02.010","volume":"86","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer. Semin. Cancer Biol. 86, 542\u2013565 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"1245_CR2","doi-asserted-by":"publisher","first-page":"6505","DOI":"10.2147\/OTT.S150817","volume":"11","author":"E Grywalska","year":"2018","unstructured":"Grywalska, E., Pasiarski, M., Gozdz, S. & Rolinski, J. Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer. Onco. Targets Ther. 11, 6505\u20136524 (2018).","journal-title":"Onco. Targets Ther."},{"key":"1245_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1046755","volume":"13","author":"H Li","year":"2022","unstructured":"Li, H. et al. Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy. Front. Immunol. 13, 1046755 (2022).","journal-title":"Front. Immunol."},{"key":"1245_CR4","doi-asserted-by":"publisher","unstructured":"Lim, A. R., Rathmell, W. K. & Rathmell, J. C. The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. eLife https:\/\/doi.org\/10.7554\/eLife.55185 (2020).","DOI":"10.7554\/eLife.55185"},{"key":"1245_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41571-019-0203-7","volume":"16","author":"X Li","year":"2019","unstructured":"Li, X. et al. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. Nat. Rev. Clin. Oncol. 16, 425\u2013441 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1245_CR6","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","volume":"168","author":"WA Lim","year":"2017","unstructured":"Lim, W. A. & June, C. H. The principles of engineering immune cells to treat cancer. Cell 168, 724\u2013740 (2017).","journal-title":"Cell"},{"key":"1245_CR7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.immuni.2018.03.007","volume":"48","author":"SA Patel","year":"2018","unstructured":"Patel, S. A. & Minn, A. J. Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. Immunity 48, 417\u2013433 (2018).","journal-title":"Immunity"},{"key":"1245_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41556-020-00615-4","volume":"23","author":"J Wu","year":"2021","unstructured":"Wu, J. et al. Asparagine enhances LCK signalling to potentiate CD8(+) T-cell activation and anti-tumour responses. Nat. Cell Biol. 23, 75\u201386 (2021).","journal-title":"Nat. Cell Biol."},{"key":"1245_CR9","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/s42255-023-00856-1","volume":"5","author":"JNR Gnanaprakasam","year":"2023","unstructured":"Gnanaprakasam, J. N. R. et al. Asparagine restriction enhances CD8(+) T cell metabolic fitness and antitumoral functionality through an NRF2-dependent stress response. Nat. Metab. 5, 1423\u20131439 (2023).","journal-title":"Nat. Metab."},{"key":"1245_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1095734","volume":"13","author":"L Yan","year":"2022","unstructured":"Yan, L., Ren, B., Hu, R., Zhang, H. & Gou, H. Are PD-1 inhibitors effective for recurrent\/metastatic nasopharyngeal carcinoma? Meta-analysis and systematic review. Front. Pharmacol. 13, 1095734 (2022).","journal-title":"Front. Pharmacol."},{"key":"1245_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11318-y","volume":"23","author":"J Luo","year":"2023","unstructured":"Luo, J. et al. Efficacy and safety of PD-1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens: a systematic review and meta-analysis. BMC Cancer 23, 1172 (2023).","journal-title":"BMC Cancer"},{"key":"1245_CR12","doi-asserted-by":"publisher","unstructured":"Tsao, S. W., Tsang, C. M. & Lo, K. W. Epstein\u2013Barr virus infection and nasopharyngeal carcinoma. Phil. Trans. R Soc. B https:\/\/doi.org\/10.1098\/rstb.2016.0270 (2017).","DOI":"10.1098\/rstb.2016.0270"},{"key":"1245_CR13","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.oraloncology.2019.06.026","volume":"95","author":"YF Chen","year":"2019","unstructured":"Chen, Y. F., Chang, K. W., Yang, I. T., Tu, H. F. & Lin, S. C. Establishment of syngeneic murine model for oral cancer therapy. Oral Oncol. 95, 194\u2013201 (2019).","journal-title":"Oral Oncol."},{"key":"1245_CR14","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nri1632","volume":"5","author":"F Macian","year":"2005","unstructured":"Macian, F. NFAT proteins: key regulators of T-cell development and function. Nat. Rev. Immunol. 5, 472\u2013484 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"1245_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.2834","volume":"15","author":"M Kurachi","year":"2014","unstructured":"Kurachi, M. et al. The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8+ T cells. Nat. Immunol. 15, 373\u2013383 (2014).","journal-title":"Nat. Immunol."},{"key":"1245_CR16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.immuni.2012.10.020","volume":"38","author":"LA Sena","year":"2013","unstructured":"Sena, L. A. et al. Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity 38, 225\u2013236 (2013).","journal-title":"Immunity"},{"key":"1245_CR17","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1016\/S0021-9258(17)30124-2","volume":"254","author":"LJ Reitzer","year":"1979","unstructured":"Reitzer, L. J., Wice, B. M. & Kennell, D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J. Biol. Chem. 254, 2669\u20132676 (1979).","journal-title":"J. Biol. Chem."},{"key":"1245_CR18","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/j.molcel.2022.03.016","volume":"82","author":"B Jiang","year":"2022","unstructured":"Jiang, B. et al. Filamentous GLS1 promotes ROS-induced apoptosis upon glutamine deprivation via insufficient asparagine synthesis. Mol. Cell 82, 1821\u20131835.e6 (2022).","journal-title":"Mol. Cell"},{"key":"1245_CR19","doi-asserted-by":"publisher","unstructured":"Hahn, A. & Zuryn, S. Mitochondrial genome (mtDNA) mutations that generate reactive oxygen species. Antioxidants https:\/\/doi.org\/10.3390\/antiox8090392 (2019).","DOI":"10.3390\/antiox8090392"},{"key":"1245_CR20","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.1182\/bloodadvances.2020001639","volume":"4","author":"D Soncini","year":"2020","unstructured":"Soncini, D. et al. Amino acid depletion triggered by L-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death. Blood Adv. 4, 4312\u20134326 (2020).","journal-title":"Blood Adv"},{"key":"1245_CR21","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.cmet.2021.02.001","volume":"33","author":"AS Krall","year":"2021","unstructured":"Krall, A. S. et al. Asparagine couples mitochondrial respiration to ATF4 activity and tumor growth. Cell Metab. 33, 1013\u20131026.e6 (2021).","journal-title":"Cell Metab."},{"key":"1245_CR22","doi-asserted-by":"publisher","first-page":"24120","DOI":"10.1074\/jbc.M201959200","volume":"277","author":"F Siu","year":"2002","unstructured":"Siu, F., Bain, P. J., LeBlanc-Chaffin, R., Chen, H. & Kilberg, M. S. ATF4 is a mediator of the nutrient-sensing response pathway that activates the human asparagine synthetase gene. J. Biol. Chem. 277, 24120\u201324127 (2002).","journal-title":"J. Biol. Chem."},{"key":"1245_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111639","volume":"41","author":"J Fernandez-Garcia","year":"2022","unstructured":"Fernandez-Garcia, J. et al. CD8(+) T cell metabolic rewiring defined by scRNA-seq identifies a critical role of ASNS expression dynamics in T cell differentiation. Cell Rep. 41, 111639 (2022).","journal-title":"Cell Rep."},{"key":"1245_CR24","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.cell.2015.08.012","volume":"162","author":"PC Ho","year":"2015","unstructured":"Ho, P. C. et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 162, 1217\u20131228 (2015).","journal-title":"Cell"},{"key":"1245_CR25","doi-asserted-by":"publisher","first-page":"119594","DOI":"10.1016\/j.bbamcr.2023.119594","volume":"1871","author":"CC Hung","year":"2024","unstructured":"Hung, C. C. et al. Noscapine alleviates unilateral ureteral obstruction-induced inflammation and fibrosis by regulating the TGF\u03b21\/Smads signaling pathways. Biochim. Biophys. Acta 1871, 119594 (2024).","journal-title":"Biochim. Biophys. Acta"},{"key":"1245_CR26","doi-asserted-by":"publisher","first-page":"W57","DOI":"10.1093\/nar\/gkv395","volume":"43","author":"H Imrichova","year":"2015","unstructured":"Imrichova, H., Hulselmans, G., Atak, Z. K., Potier, D. & Aerts, S. i-cisTarget 2015 update: generalized cis-regulatory enrichment analysis in human, mouse and fly. Nucleic Acids Res. 43, W57\u2013W64 (2015).","journal-title":"Nucleic Acids Res."},{"key":"1245_CR27","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1093\/nar\/gks543","volume":"40","author":"C Herrmann","year":"2012","unstructured":"Herrmann, C., Van de Sande, B., Potier, D. & Aerts, S. i-cisTarget: an integrative genomics method for the prediction of regulatory features and cis-regulatory modules. Nucleic Acids Res. 40, e114 (2012).","journal-title":"Nucleic Acids Res."},{"key":"1245_CR28","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s00259-022-05780-2","volume":"49","author":"E Lopci","year":"2022","unstructured":"Lopci, E. et al. Joint EANM\/SNMMI\/ANZSNM practice guidelines\/procedure standards on recommended use of [18F]FDG PET\/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. Eur. J. Nucl. Med. Mol. Imaging 49, 2323\u20132341 (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1245_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13139-017-0493-6","volume":"52","author":"HJ Im","year":"2018","unstructured":"Im, H. J., Bradshaw, T., Solaiyappan, M. & Cho, S. Y. Current methods to define metabolic tumor volume in positron emission tomography: which one is better? Nucl. Med. Mol. Imaging 52, 5\u201315 (2018).","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"1245_CR30","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1158\/1078-0432.CCR-12-3702","volume":"19","author":"QT Le","year":"2013","unstructured":"Le, Q. T. et al. An international collaboration to harmonize the quantitative plasma Epstein\u2013Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin. Cancer Res. 19, 2208\u20132215 (2013).","journal-title":"Clin. Cancer Res."},{"key":"1245_CR31","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/hed.21890","volume":"34","author":"CL Hsu","year":"2012","unstructured":"Hsu, C. L. et al. Plasma Epstein\u2013Barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma. Head Neck 34, 1064\u20131070 (2012).","journal-title":"Head Neck"}],"updated-by":[{"DOI":"10.1038\/s42255-026-01633-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000}}],"container-title":["Nature Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42255-025-01245-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42255-025-01245-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42255-025-01245-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:37:08Z","timestamp":1789537028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42255-025-01245-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["1245"],"URL":"https:\/\/doi.org\/10.1038\/s42255-025-01245-6","relation":{},"ISSN":["2522-5812"],"issn-type":[{"value":"2522-5812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"8 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s42255-026-01633-6","URL":"https:\/\/doi.org\/10.1038\/s42255-026-01633-6","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.-C.H. is a co-founder of Pilatus Biosciences and serves as scientific advisor board member for Pilatus Biosciences, Celyad Oncology and Elixiron Immunotherapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}